Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects. by Castro, R, Vieira, J, Chacra, A, Besser, G, Grossman, AB, Lengyel, A

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. by Bethel, M, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Kahn, SE, Levitt, N, McMurray, J, Califf, R, Raptis, SA, Thomas, L, Sun, J, Haffner, S

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk by Bethel, M, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Kahn, SE, Levitt, N, McMurray, J, Califf, R, Raptis, SA, Thomas, L, Sun, J, Haffner, S

Updated risk factors should be used to predict development of diabetes. by Bethel, M, Hyland, K, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Levitt, N, McMurray, J, Boutati, E, Thomas, L, Sun, J, Haffner, S, NAVIGATOR Study Group

Effect of valsartan on the incidence of diabetes and cardiovascular events. by McMurray, J, Holman, R, Haffner, S, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H

Effect of nateglinide on the incidence of diabetes and cardiovascular events. by Holman, R, Haffner, S, McMurray, J, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H